ABVC Biopharma Net Income
| ABVC Stock | USD 1.90 0.01 0.53% |
As of the 4th of February, ABVC Biopharma shows the Mean Deviation of 3.07, variance of 15.17, and Market Risk Adjusted Performance of (0.80). ABVC Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.
ABVC Biopharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 63.5509 | Revenue | Earnings Share (0.28) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -4.7 M | -5 M | |
| Net Loss | -4.7 M | -5 M | |
| Net Loss | -14.8 M | -14 M | |
| Net Loss | (0.38) | (0.40) | |
| Net Income Per E B T | 1.05 | 1.08 |
ABVC | Net Income | Build AI portfolio with ABVC Stock |
Analyzing ABVC Biopharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing ABVC Biopharma's current valuation and future prospects.
Latest ABVC Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of ABVC Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ABVC Biopharma financial statement analysis. It represents the amount of money remaining after all of ABVC Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ABVC Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ABVC Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (5.26 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ABVC Net Income Regression Statistics
| Arithmetic Mean | (5,094,173) | |
| Coefficient Of Variation | (98.14) | |
| Mean Deviation | 3,865,805 | |
| Median | (4,412,590) | |
| Standard Deviation | 4,999,388 | |
| Sample Variance | 25T | |
| Range | 16.4M | |
| R-Value | (0.57) | |
| Mean Square Error | 18.1T | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | (559,651) | |
| Total Sum of Squares | 399.9T |
ABVC Net Income History
Other Fundumenentals of ABVC Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ABVC Biopharma Net Income component correlations
ABVC Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ABVC Biopharma is extremely important. It helps to project a fair market value of ABVC Stock properly, considering its historical fundamentals such as Net Income. Since ABVC Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ABVC Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ABVC Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 1.045 | Return On Assets | Return On Equity |
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
ABVC Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ABVC Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ABVC Biopharma.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in ABVC Biopharma on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding ABVC Biopharma or generate 0.0% return on investment in ABVC Biopharma over 90 days. ABVC Biopharma is related to or competes with Reviva Pharmaceuticals, Grace Therapeutics, PDS Biotechnology, Actinium Pharmaceuticals, Jupiter Neurosciences, Tvardi Therapeutics, and Lantern Pharma. ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet me... More
ABVC Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ABVC Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ABVC Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 17.75 | |||
| Value At Risk | (6.44) | |||
| Potential Upside | 6.44 |
ABVC Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ABVC Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ABVC Biopharma's standard deviation. In reality, there are many statistical measures that can use ABVC Biopharma historical prices to predict the future ABVC Biopharma's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.81) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ABVC Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ABVC Biopharma February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.80) | |||
| Mean Deviation | 3.07 | |||
| Coefficient Of Variation | (788.54) | |||
| Standard Deviation | 3.9 | |||
| Variance | 15.17 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.81) | |||
| Maximum Drawdown | 17.75 | |||
| Value At Risk | (6.44) | |||
| Potential Upside | 6.44 | |||
| Skewness | (0.16) | |||
| Kurtosis | 0.226 |
ABVC Biopharma Backtested Returns
ABVC Biopharma secures Sharpe Ratio (or Efficiency) of -0.15, which signifies that the company had a -0.15 % return per unit of volatility over the last 3 months. ABVC Biopharma exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm ABVC Biopharma's Market Risk Adjusted Performance of (0.80), mean deviation of 3.07, and Variance of 15.17 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ABVC Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ABVC Biopharma is expected to be smaller as well. At this point, ABVC Biopharma has a negative expected return of -0.59%. Please make sure to confirm ABVC Biopharma's accumulation distribution, and the relationship between the potential upside and day median price , to decide if ABVC Biopharma performance from the past will be repeated in the future.
Auto-correlation | 0.80 |
Very good predictability
ABVC Biopharma has very good predictability. Overlapping area represents the amount of predictability between ABVC Biopharma time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ABVC Biopharma price movement. The serial correlation of 0.8 indicates that around 80.0% of current ABVC Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.8 | |
| Spearman Rank Test | 0.84 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ABVC Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ABVC Biopharma reported net income of (5.26 Million). This is 101.54% lower than that of the Biotechnology sector and 107.51% lower than that of the Health Care industry. The net income for all United States stocks is 100.92% higher than that of the company.
ABVC Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ABVC Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ABVC Biopharma could also be used in its relative valuation, which is a method of valuing ABVC Biopharma by comparing valuation metrics of similar companies.ABVC Biopharma is currently under evaluation in net income category among its peers.
ABVC Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in ABVC Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ABVC Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ABVC Biopharma's value.| Shares | Honkamp Krueger Financial Services Inc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-03-31 | 0.0 | Two Sigma Securities, Llc | 2025-06-30 | 0.0 | Vanguard Group Inc | 2025-06-30 | 111.5 K | Geode Capital Management, Llc | 2025-06-30 | 110.5 K | Xtx Topco Ltd | 2025-06-30 | 52.6 K | Renaissance Technologies Corp | 2025-06-30 | 41.7 K | Northern Trust Corp | 2025-06-30 | 37.1 K | State Street Corp | 2025-06-30 | 12.9 K | Sbi Securities Co Ltd | 2025-06-30 | 483 | Tower Research Capital Llc | 2025-06-30 | 354 |
ABVC Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (1.47) % | ||||
| Current Valuation | 51.68 M | ||||
| Shares Outstanding | 24.3 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 3.13 % | ||||
| Number Of Shares Shorted | 342.72 K | ||||
| Price To Book | 4.11 X | ||||
| Price To Sales | 57.56 X | ||||
| Revenue | 509.59 K | ||||
| Gross Profit | 797.92 K | ||||
| EBITDA | (4.34 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 2.99 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 3.2 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (1.81 M) | ||||
| Short Ratio | 5.13 X | ||||
| Earnings Per Share | (0.28) X | ||||
| Target Price | 2.02 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 45.93 M | ||||
| Total Asset | 7.54 M | ||||
| Retained Earnings | (68.95 M) | ||||
| Working Capital | (4.38 M) | ||||
| Net Asset | 7.54 M |
About ABVC Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABVC Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABVC Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABVC Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 1.045 | Return On Assets | Return On Equity |
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.